Multiple Sclerosis Journal - October 2017 - 1451

N Dubuisson, F Puentes et al.
75. Bielekova B and Martin R. Development of
biomarkers in multiple sclerosis. Brain 2004;
127(Pt. 7): 1463-1478.
76. Martínez-Yélamos A, Saiz A, Bas J, et al. Tau protein
in cerebrospinal fluid: A possible marker of poor
outcome in patients with early relapsing-remitting
multiple sclerosis. Neurosci Lett 2004; 363(1):
14-17.
77. Bitsch A, Horn C, Kemmling Y, et al. Serum tau
protein level as a marker of axonal damage in acute
ischemic stroke. Eur Neurol 2002; 47(1): 45-51.
78. Shaw GJ, Jauch EC and Zemlan FP. Serum cleaved
tau protein levels and clinical outcome in adult
patients with closed head injury. Ann Emerg Med
2002; 39(3): 254-257.
79. Bartosik-Psujek H, Psujek M, Jaworski J, et al. Total
tau and S100b proteins in different types of multiple
sclerosis and during immunosuppressive treatment
with mitoxantrone. Acta Neurol Scand 2011; 123(4):
252-256.
80. Reiber H. Dynamics of brain-derived proteins in
cerebrospinal fluid. Clin Chim Acta 2001; 310(2):
173-186.
81. Guimarães I, Cardoso MI and Sá MJ. Tau protein
seems not to be a useful routine clinical marker of
axonal damage in multiple sclerosis. Mult Scler 2006;
12(3): 354-356.
82. Szalardy L, Zadori D, Simu M, et al. Evaluating
biomarkers of neuronal degeneration and
neuroinflammation in CSF of patients with multiple
sclerosis-osteopontin as a potential marker of clinical
severity. J Neurol Sci 2013; 331(1-2): 38-42.
83. Süssmuth SD, Reiber H and Tumani H. Tau
protein in cerebrospinal fluid (CSF): A blood-CSF
barrier related evaluation in patients with various
neurological diseases. Neurosci Lett 2001; 300(2):
95-98.
84. Jaworski J, Psujek M, Janczarek M, et al. Total-tau in
cerebrospinal fluid of patients with multiple sclerosis
decreases in secondary progressive stage of disease
and reflects degree of brain atrophy. Ups J Med Sci
2012; 117(3): 284-292.
85. Kosehasanogullari G, Ozakbas S and Idiman E. Tau
protein levels in the cerebrospinal fluid of the patients
with multiple sclerosis in an attack period: Low levels
of tau protein may have significance, too. Clin Neurol
Neurosurg 2015; 136: 107-109.
86. Brettschneider J, Maier M, Arda S, et al. Tau protein
level in cerebrospinal fluid is increased in patients
with early multiple sclerosis. Mult Scler 2005; 11(3):
261-265.
87. Mellergård J, Tisell A, Blystad I, et al. Cerebrospinal
fluid levels of neurofilament and tau correlate

journals.sagepub.com/home/msj

with brain atrophy in natalizumab-treated multiple
sclerosis. Eur J Neurol 2017; 24: 112-121.
88. Frederiksen J, Kristensen K, Bahl JMC, et al. Tau
protein: A possible prognostic factor in optic neuritis
and multiple sclerosis. Mult Scler 2012; 18(5):
592-599.
89. Nordengen K, Heuser C, Rinholm JE, et al.
Localisation of N-acetylaspartate in oligodendrocytes/
myelin. Brain Struct Funct 2015; 220(2): 899-917.
90. Moffett JR, Ross B, Arun P, et al. N-Acetylaspartate
in the CNS: From neurodiagnostics to neurobiology.
Prog Neurobiol 2007; 81(2): 89-131.
91. Bjartmar C, Kidd G, Mörk S, et al. Neurological
disability correlates with spinal cord axonal loss
and reduced N-acetyl aspartate in chronic multiple
sclerosis patients. Ann Neurol 2000; 48(6): 893-901.
92. Jasperse B, Jakobs C, Eikelenboom MJ, et al.
N-acetylaspartic acid in cerebrospinal fluid of
multiple sclerosis patients determined by gaschromatography-mass spectrometry. J Neurol 2007;
254(5): 631-637.
93. Khalil M, Enzinger C, Langkammer C, et al. CSF
neurofilament and N-acetylaspartate related brain
changes in clinically isolated syndrome. Mult Scler
2013; 19(4): 436-442.
94. De Stefano N, Guidi L, Stromillo ML, et al. Imaging
neuronal and axonal degeneration in multiple
sclerosis. Neurol Sci 2003; 24 (Suppl. 5): S283-S286.
95. Lafon-Cazal M, Adjali O, Galéotti N, et al. Proteomic
analysis of astrocytic secretion in the mouse.
Comparison with the cerebrospinal fluid proteome. J
Biol Chem 2003; 278(27): 24438-24448.
96. Lee CG, Da Silva CA, Dela Cruz CS, et al. Role
of chitin and chitinase/chitinase-like proteins in
inflammation, tissue remodeling, and injury. Annu
Rev Physiol 2011; 73: 479-501.
97. Comabella M, Fernández M, Martin R, et al.
Cerebrospinal fluid chitinase 3-like 1 levels are
associated with conversion to multiple sclerosis.
Brain 2010; 133(Pt. 4): 1082-1093.
98. Møllgaard M, Degn M, Sellebjerg F, et al.
Cerebrospinal fluid chitinase-3-like 2 and
chitotriosidase are potential prognostic biomarkers
in early multiple sclerosis. Eur J Neurol 2016; 23(5):
898-905.
99. Modvig S, Degn M, Roed H, et al. Cerebrospinal
fluid levels of chitinase 3-like 1 and neurofilament
light chain predict multiple sclerosis development and
disability after optic neuritis. Mult Scler 2015; 21(14):
1761-1770.
100. Cantó E, Tintoré M, Villar LM, et al. Chitinase
3-like 1: Prognostic biomarker in clinically isolated
syndromes. Brain 2015; 138(Pt. 4): 918-931.

1451
https://journals.sagepub.com/home/msj
Table of Contents for the Digital Edition of Multiple Sclerosis Journal - October 2017
